NASDAQ:KMPH Zevra Therapeutics (KMPH) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free KMPH Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$4.48▼$6.2752-Week Range N/AVolume64,100 shsAverage Volume189,500 shsMarket Capitalization$200.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zevra Therapeutics alerts: Email Address Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Zevra Therapeutics Stock (NASDAQ:KMPH)KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.Read More Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. KMPH Stock News HeadlinesMarch 4, 2024 | marketwatch.comZevra Therapeutics Shares Fall After FDA Extends Arimoclomol ReviewFebruary 20, 2024 | yahoo.comBrisbane, Australia - Weather Forecasts | Maps | News - Yahoo WeatherApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 17, 2024 | yahoo.comChristchurch, New Zealand - Weather Forecasts | Maps | News - Yahoo WeatherJanuary 11, 2024 | yahoo.comGreater Bendigo, Australia - Weather Forecasts | Maps | News - Yahoo WeatherJanuary 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Zevra Therapeutics Amid Positive Regulatory Developments and Strong Market PositioningJanuary 8, 2024 | markets.businessinsider.comZevra Therapeutics Says FDA Accepts Resubmission Of Arimoclomol NDA In Niemann-Pick Disease Type CJanuary 6, 2024 | yahoo.comWellington, New Zealand - Weather Forecasts | Maps | News - Yahoo WeatherApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 27, 2023 | msn.comZevra seeks FDA nod for rare disease therapy arimoclomolDecember 27, 2023 | marketwatch.comZevra Therapeutics Refiles Arimoclomol Application With FDADecember 23, 2023 | yahoo.comQueenstown, New Zealand - Weather Forecasts | Maps | News - Yahoo WeatherDecember 11, 2023 | yahoo.comMelbourne, Australia - Weather Forecasts | Maps | News - Yahoo WeatherDecember 11, 2023 | yahoo.comOroquieta City, Philippines - Weather Forecasts | Maps | News - Yahoo WeatherDecember 1, 2023 | yahoo.comTehran, Iran - Weather Forecasts | Maps | News - Yahoo WeatherNovember 9, 2023 | markets.businessinsider.comZevra Therapeutics: Promising Growth Avenues and Potential Approvals Bolster Buy RatingOctober 26, 2023 | yahoo.comPhnom Penh, Cambodia - Weather Forecasts | Maps | News - Yahoo WeatherAugust 26, 2023 | yahoo.comNowra, Australia - Weather Forecasts | Maps | News - Yahoo WeatherAugust 26, 2023 | yahoo.comTemuka, New Zealand - Weather Forecasts | Maps | News - Yahoo WeatherAugust 14, 2023 | seekingalpha.comZevra Therapeutics GAAP EPS of -$0.15 beats by $0.19, revenue of $8.5M beats by $5.47MJuly 30, 2023 | yahoo.comManama, Bahrain - Weather Forecasts | Maps | News - Yahoo WeatherJuly 29, 2023 | yahoo.comKanayannur, India - Weather Forecasts | Maps | News - Yahoo WeatherJuly 29, 2023 | yahoo.comMonte-Carlo, Monaco - Weather Forecasts | Maps | News - Yahoo WeatherJuly 27, 2023 | yahoo.comGeneva, Switzerland - Weather Forecasts | Maps | News - Yahoo WeatherJuly 27, 2023 | yahoo.comBellevue, United States - Weather Forecasts | Maps | News - Yahoo WeatherJuly 25, 2023 | yahoo.comNairobi, Kenya - Weather Forecasts | Maps | News - Yahoo WeatherJuly 25, 2023 | yahoo.comMunich, Germany - Weather Forecasts | Maps | News - Yahoo WeatherSee More Headlines Receive KMPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zevra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/30/2022Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KMPH CUSIPN/A CIK1434647 Webwww.kempharm.com Phone(321) 939-3416Fax319-665-2577Employees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net Margins-328.56% Pretax Margin-335.26% Return on Equity-16.12% Return on Assets-14.17% Debt Debt-to-Equity Ratio0.14 Current Ratio10.10 Quick Ratio10.10 Sales & Book Value Annual Sales$10.72 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow23.28 Book Value$3.63 per share Price / BookN/AMiscellaneous Outstanding Shares34,505,000Free Float34,125,000Market Cap$200.47 million OptionableOptionable Beta2.16 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesRichard W. PascoeChief Executive Officer & DirectorTravis C. MicklePresident & DirectorR. LaDuane CliftonChief Financial Officer, Secretary & TreasurerSven GuentherChief Scientific OfficerDaniel GalloSenior Vice President-Medical AffairsKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLOrganigramNASDAQ:OGIZevra TherapeuticsNASDAQ:ZVRATrevi TherapeuticsNASDAQ:TRVILifecore BiomedicalNASDAQ:LFCRView All Competitors KMPH Stock Analysis - Frequently Asked Questions How were Zevra Therapeutics' earnings last quarter? Zevra Therapeutics, Inc. (NASDAQ:KMPH) released its earnings results on Wednesday, March, 30th. The specialty pharmaceutical company reported ($0.08) EPS for the quarter, meeting the consensus estimate of ($0.08). Zevra Therapeutics had a negative net margin of 328.56% and a negative trailing twelve-month return on equity of 16.12%. What other stocks do shareholders of Zevra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zevra Therapeutics investors own include Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), SCYNEXIS (SCYX), AVEO Pharmaceuticals (AVEO), Aldeyra Therapeutics (ALDX), Exelixis (EXEL), BioCryst Pharmaceuticals (BCRX), Cara Therapeutics (CARA), DURECT (DRRX) and Paratek Pharmaceuticals (PRTK). When did Zevra Therapeutics IPO? Zevra Therapeutics (KMPH) raised $60 million in an initial public offering on Thursday, April 16th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and RBC Capital Markets acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer were co-managers. This page (NASDAQ:KMPH) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
